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Abstract 24 
Pro-inflammatory cytokines, such as IL-1β, have been implicated as underlying pathophysiological 25 
mechanisms and potential biomarkers of Post-Traumatic Stress Disorder (PTSD). This systematic 26 
review examines data regarding IL-1β production/concentration in human and animal studies of PTSD. 27 
In accordance with PRISMA guidelines, relevant articles from PubMed were reviewed from inception 28 
until 10th July 2017.  29 
Nineteen studies were eligible for inclusion. Animal studies demonstrated increased hippocampal IL-30 
1β in rodent models of PTSD. Several immunomodulatory drugs were shown to reduce elevated IL-1β 31 
levels and anxiety-like behaviours in animals. Human cross-sectional studies showed contradictory 32 
results; serum and plasma IL-1β concentrations in PTSD patients were either elevated or did not differ 33 
from control groups. In-vitro IL-1β production by stimulated cells demonstrated no difference 34 
between PTSD and control participants, although spontaneous in-vitro production of IL-1β was 35 
increased in the PTSD group. The findings from two longitudinal studies were inconsistent.  36 
Given the conflicting findings, it is premature to consider IL-1β as a biomarker of PTSD. Anti-37 
inflammatory agents may reduce IL-1β, and be a potential basis for future therapeutic agents in PTSD 38 
treatment. More longitudinal research is needed to better understand the role of IL-1β in the 39 
development and/or maintenance of PTSD. 40 
 41 
Introduction 42 
Post-traumatic Stress Disorder (PTSD) is a chronic psychiatric disorder that can develop in response to 43 
exposure to a catastrophic threat. Triggers can include war, sexual or physical assault, and natural 44 
disasters. Throughout history the condition has had various labels, including ‘Shell Shock’ and ‘Stress 45 
Response Syndrome’, although it was not until the late twentieth century that it was included in the 46 
diagnostic classifications used in psychiatry practice today (American Psychiatric Association 2013). 47 
PTSD was first included in the Diagnostic and Statistical Manual (DSM) of the American Psychiatric 48 
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Association in 1980, followed by inclusion in the World Health Organisation’s International 49 
Classification of Diseases (ICD) over a decade later, in 1992 (World Health Organization 1992). 50 
Although similar, the two systems provide differing criteria for which to diagnose patients potentially 51 
suffering from PTSD. 52 
PTSD diagnosis and assessment 53 
PTSD diagnosis. Specifically, the ICD-10 classification requires patients to have been exposed to a 54 
stressful event which is perceived as threatening and causes them distress (World Health Organization 55 
1992). No minimum length of exposure is stated, however, symptoms should begin within six months 56 
of the traumatic exposure. The trauma is regularly revisited by the patient through intrusive dreams, 57 
memories, or flashbacks, particularly if the individual finds themselves in a similar situation to the 58 
initial trauma. Patients actively avoid situations associated with the trauma or block out memories 59 
pertaining to the event. In addition, patients should experience two or more of the following 60 
symptoms in order for the diagnosis to be made: difficulty falling asleep, lability of mood or emotional 61 
outbursts, concentration deficits, hyper-arousal or an increased startle response. These symptoms 62 
ought to be of new onset following the trauma, and are indicative of amplified psychological sensitivity 63 
(World Health Organization 1992). 64 
Similarly, to fulfil a diagnosis of PTSD according to DSM-5 criteria (American Psychiatric Association 65 
2013), patients should have experienced an event involving actual or threat of death, sexual or 66 
physical violence, or serious injury. This may be through direct exposure, witnessing an event, or being 67 
informed that an acquaintance or relative was involved in a traumatic event. Akin to the ICD-10 68 
classification, re-experiencing the trauma is required, although not necessarily as nightmares or 69 
flashbacks. Severe emotional distress or physical reactivity can also be diagnostic. Avoidance of 70 
circumstances or thoughts related to the trauma and two or more negative emotions must also be 71 
present, or become progressively worse following the trauma. These may include feelings of isolation, 72 
persecutory thoughts, or being unable to remember facts relating to the event. The patient also needs 73 
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to suffer from 2 or more symptoms of hyper-arousal, again equivalent to ICD-10 criteria. Unique to 74 
DSM-5, the patient’s symptoms must be severe enough to cause distress and deterioration of normal 75 
function, which cannot be explained by other factors, such as changes in medication or co-morbid 76 
pathology, and should persist for a minimum of one month following the initial trauma. All elements 77 
of the criteria must be fulfilled for over 1 month duration for a confident diagnosis to be made 78 
(American Psychiatric Association 2013). 79 
Assessment of PTSD. The ICD-10 or DSM-5 criteria are commonly used for research purposes and for 80 
the clinical diagnosis of PTSD. In clinical as well as in research practice, the structured clinical interview 81 
for the DSM-IV axis I disorders (SCID-IV), and more recently the SCID-5, are standard validated 82 
diagnostic tools with good sensitivity and inter-rater reliability that are used to make the diagnosis 83 
according to DSM-IV and DSM-5 (Elhai et al 2008; Lobbestael et al 2011). In research, self-administered 84 
PTSD questionnaires are also used, including the PTSD Checklist (PCL; Blanchard et al 1996; a civilian 85 
and military version are also available, PCL-C and PCL-M respectively; Weathers et al 2013), the Los 86 
Angeles Symptom Checklist (LASC; King et al 1995), and the Posttraumatic Diagnostic Scale (PDS; Foa 87 
et al 1997; Sheeran and Zimmerman 2002). Although quicker to perform, these measures may have a 88 
tendency to over-diagnose patients (Griffin et al 2004). Currently, the gold standard tool for assessing 89 
PTSD symptom severity is the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; American 90 
Psychiatric Association 2013; Blake et al 1995).  91 
Animal models of PTSD. Rodents are typically used and are subjected to various validated stress-92 
paradigms in order to simulate a PTSD-like state in the animals (Goswami et al 2013). Two examples 93 
are the Stress-Enhanced Fear Learning (SEFL) model and the Single Prolonged Stress (SPS) procedure. 94 
In SEFL rodents are given multiple electric shocks, at a later time they are then placed in a different 95 
environment and given a single shock as a reminder of the original stressful event. Freezing time 96 
and/or immobility is used as a measure of a learned fear response (Rau et al 2005). In the SPS 97 
procedure, several stressors are administered to the rodent, including restraint, forced swimming, and 98 
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ether, followed by a period of inactivity (Yamamoto et al 2009). In PTSD models, various behavioural 99 
tests, including the open field test, are then subsequently performed to confirm the presence of pre-100 
defined PTSD traits, such as hyperarousal and social withdrawal. Following the implementation of an 101 
animal model, medication trials, behavioural experiments, and cellular analysis can then be 102 
performed.  103 
The pathophysiology of PTSD 104 
An important biological factor involved in the pathophysiology of PTSD seems to be brain morphology 105 
and function. Studies have demonstrated gross morphological differences between the brains of PTSD 106 
patients and healthy controls (Woon and Hedges 2009; Zandieh et al 2016). These include changes to 107 
the hippocampus, amygdala, and prefrontal cortex, which may account for the symptoms of PTSD, 108 
given their involvement in memory, emotion and personality, and behavioural functioning. 109 
Specifically, hippocampal volume and grey matter density were found to be reduced in PTSD patients 110 
compared to healthy controls (Gilbertson et al 2002). Also, studies have demonstrated reduced 111 
amygdala volumes in PTSD patients (Morey et al 2012). Interestingly, stress has been shown to lead 112 
to increases in pro-inflammatory cytokines (Lopez-Castejon and Brough 2011; Wilson et al 2013) and 113 
kynurenine pathway metabolites which can both be neurotoxic in the hippocampus, the amygdala 114 
and prefrontal cortex (Kim and Won 2017). 115 
Current review 116 
As PTSD is a heterogeneous disorder, it is likely that there are multiple mechanisms underlying the 117 
development and maintenance of the disorder and therefore, several possible biomarkers. 118 
Inflammatory processes are one possible biomarker of PTSD (Michopoulos et al 2015). Existing 119 
literature indicates that pro-inflammatory cytokines could be a contributing factor to the 120 
pathophysiology of PTSD and play a role in PTSD-related elevated risk for cardiovascular, autoimmune, 121 
and neurodegenerative diseases, although the precise mechanisms remain unclear.  122 
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The current review will focus upon IL-1β as it is a key cytokine that has been implicated in 123 
neuroplasticity and the process of memory formation (Lopez-Castejon and Brough 2011). Secreted 124 
from macrophages, microglia and astrocytes, IL-1β has roles in host defence, tissue injury during acute 125 
and chronic inflammatory disease, and auto-inflammatory conditions. A recent meta-analysis found 126 
that several pro-inflammatory cytokines, including IL-1β, are elevated in PTSD patients in comparison 127 
to control groups (Passos et al 2015). This meta-analysis focused on human cross-sectional in-vivo 128 
measurements and did not account for in-vitro measurements, longitudinal investigations, nor animal 129 
studies. Thus, the current review is warranted to provide a more comprehensive and up-to-date 130 
summary of the available literature. The purpose of this systematic review is to summarise the 131 
evidence regarding IL-1β and PTSD in human and animal literature, with a view to adding to current 132 
understanding of the condition and its pathophysiology, and to assess its potential as a biomarker for 133 
PTSD and its treatment. If an association is identified between IL-1β and PTSD, this could provide a 134 
potential future treatment target for PTSD, as blocking medications are available. 135 
Methods 136 
Selection Criteria 137 
Articles were eligible for inclusion in the review if they reported on original research pertaining to both 138 
IL-1β and PTSD in human or animal studies. Specifically, studies of any design that assessed IL-1β 139 
production in-vitro or IL-1β concentration in the serum, plasma, or cerebrospinal fluid (in-vivo) of 140 
individuals with PTSD were eligible for inclusion. Studies were included if they reported a group and/or 141 
longitudinal comparison of IL-1β concentration and/or production. Publications reporting on the 142 
measurement of IL-1β in animal models of PTSD were also included. 143 
Studies were excluded if: (i) they did not report group or longitudinal comparisons in concentration or 144 
production of IL-1β; (ii) they presented purely genetic or IL-1β receptor data; (iii) participants were 145 
not formally diagnosed with PTSD according to a validated assessment tool or diagnostic criteria; and 146 
(v) life trauma, childhood trauma or distress caused by chronic illness, rather than PTSD, was 147 
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investigated. Review articles, meta-analyses, conference proceedings/abstracts, editorials, letters, 148 
book chapters, and unpublished theses were also not included. 149 
Search Strategy 150 
Using PubMed and in accordance with the PRISMA guidelines (Moher et al 2009), a search from 151 
inception until 10th July 2017 was conducted. The following search terms were used to identify all 152 
potentially eligible records: 153 
(("post-traumatic stress disorder"[Title/Abstract]) OR ("PTSD"[Title/Abstract]) OR ("posttraumatic 154 
stress disorder"[Title/Abstract]) OR ("post traumatic stress disorder"[Title/Abstract])) AND 155 
(("interleukin-1"[Title/Abstract]) OR ("interleukin-1β"[Title/Abstract]) ("interleukin-1 156 
β"[Title/Abstract]) OR ("interleukin-1 beta"[Title/Abstract]) OR ("interleukin-1beta"[Title/Abstract]) 157 
OR ("interleukin 1"[Title/Abstract]) OR ("interleukin 1β"[Title/Abstract]) OR ("interleukin 1 158 
β"[Title/Abstract]) OR ("interleukin 1 beta"[Title/Abstract]) OR ("interleukin 1beta"[Title/Abstract]) 159 
OR ("IL-1"[Title/Abstract]) OR ("IL-1β"[Title/Abstract]) OR ("IL-1 β"[Title/Abstract]) OR ("IL-1 160 
beta"[Title/Abstract]) OR ("IL-1beta"[Title/Abstract]) OR ("IL 1"[Title/Abstract]) OR ("IL 161 
1β"[Title/Abstract]) OR ("IL 1 β"[Title/Abstract]) OR ("IL 1 beta"[Title/Abstract]) OR ("IL 162 
1beta"[Title/Abstract])) 163 
 164 
This search was supplemented by internet searches and hand-searches of reference lists of included 165 
papers and potentially relevant reviews. Citation tracking in Web of Science was also performed. The 166 
abstracts of identified articles were subsequently screened for eligibility according to pre-set inclusion 167 
and exclusion criteria, as described above. Potentially eligible records were further reviewed in full 168 
text. Subsequently, the articles included in the qualitative synthesis were categorized into animal and 169 
human studies and then further divided according to their study design. An overview of the literature 170 
search is shown in Figure 1. 171 
Data Extraction 172 
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The data from all eligible studies was extracted into an electronic summary table by the first author 173 
(AW), which was then checked by another author (BD). Information collected related to the sample 174 
characteristics, method of PTSD assessment and measurement of IL-1β, and relevant findings.  175 
INSERT FIGURE I HERE 176 
Results 177 
Characteristics of included studies  178 
A total of 19 articles were eligible for inclusion in this review. Eight of the included articles used animal 179 
models of PTSD to investigate the relationship between IL-1β and PTSD (Aga-Mizrachi et al 2014; 180 
Deslauriers et al 2017; Jones et al 2015; Lazuko et al 2017; Lee et al 2016; Liu et al 2016; Peng et al 181 
2013; Zimmerman et al 2012). Twelve studies assessed IL-1β concentration or production in humans. 182 
Nine of these were in-vivo cross-sectional human studies measuring plasma, or serum concentration 183 
of IL-1β (Bersani et al 2016; Hoge et al 2009; Jergović et al 2015; Lindqvist et al 2014; Oganesyan et al 184 
2009; Spivak et al 1997; Tucker et al 2004; von Känel et al 2007; Zhou et al 2014). Of these, two studies 185 
also assessed serum IL-1β longitudinally in individuals with PTSD (Jergović et al 2015; Tucker et al 2004) 186 
and one study reported both human and animal data (Zimmerman et al 2012). Two additional human 187 
cross-sectional study assessed IL-1β production in-vitro (Gill et al 2008; Gola et al 2013).  188 
Study findings: Animal studies  189 
All included animals studies used rodents in their animal models of PTSD. A variety of animal models 190 
were used (e.g. SPS, SEFL, enhanced SPS, predator scent exposure) to induce PTSD-like traits; the 191 
majority involved applying a shock to the foot of the animal. Most studies measured hippocampal IL-192 
1β levels (Jones et al 2015; Lee et al 2016; Liu et al 2016; Peng et al 2013), with three remaining studies 193 
measuring serum concentrations of IL-1β (Aga-Mizrachi et al 2014; Lazuko et al 2017; Zimmerman et 194 
al 2012) and the other measuring brain protein levels (Deslauriers et al 2017). The results of these 195 
studies are presented in Table I. 196 
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Elevated serum IL-1β levels in the PTSD-groups, as compared to the control groups were identified 197 
(Aga-Mizrachi et al 2014; Lazuko et al 2017). In Aga-Mizrachi et al (2014), these elevated serum IL-1β 198 
levels were subsequently reduced upon administration of antidepressants (desipramine and 199 
fluoxetine) or methylphenidate, a stimulant of the central nervous system. The combination of the 200 
SSRI fluoxetine and methylphenidate reduced IL-1β to undetectable levels. In contrast, Zimmerman et 201 
al (2012) reported that IL-1β serum levels did not differ between the stressed and non-stressed 202 
groups. However, when stressed mice were administered mEN101, an oligonucleotide with anxiolytic 203 
effects, levels of IL-1β were significantly lower than in the non-treated stress group. Three studies also 204 
reported increased IL-1β levels in the hippocampus of stress-induced rats (Jones et al 2015; Lee et al 205 
2016; Peng et al 2013). Specifically, Jones et al (2015) showed that hippocampal IL-1β 206 
immunoreactivity and mRNA expression increased in a time-dependent manner post-stressor. This 207 
effect was most prominently observed in the dentate gyrus of the dorsal hippocampus. Furthermore, 208 
stress-induced rats given morphine 48-hours post-stressor, showed a significant reduction in 209 
hippocampal IL-1β levels. Similarly, in Peng et al., the hippocampal IL-1β levels reduced in a dose-210 
dependent manner with the administration of gastrodin, a main constituent of a Chinese herbal 211 
medicine. These reductions in IL-1β levels were also associated with improvements in PTSD-like 212 
behaviour. Additionally, Lee et al (2016) found that the elevated levels of IL-1β hippocampal mRNA 213 
expression observed in the stressed rats, was reduced by the administration of fluoxetine to similar 214 
IL-1β levels seen in the non-stressed rats. In contrast, Liu et al (2016) found no significant difference 215 
in hippocampal IL-1β levels between SPS-exposed rats and controls; however, elevated levels of 216 
malondialdehyde, a marker of oxidative stress, were found in the hippocampus (Yang et al 2013). 217 
Deslauriers et al (2017) also found no difference in IL-1β levels in predator stress exposed male 218 
C57BL/6 mice compared to non-exposed mice. 219 
INSERT TABLE I HERE 220 
Study findings: Human Studies  221 
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PTSD assessment. In the majority of studies, PTSD diagnosis had been made using versions of the DSM 222 
or ICD. The majority of studies also used validated questionnaires to measure PTSD symptom severity 223 
in the study. The CAPS was used in 8 studies, 2 of these used it in combination with the SCID (Bersani 224 
et al 2016; Tucker et al 2004) and one with the PCL-M (Zhou et al 2014). One study (Hoge et al 2009) 225 
used the Short Post-Traumatic Stress Disorder Rating (SPRINT; Connor and Davidson 2001) , one used 226 
the LASC (Jergović et al 2015) and one the Hebrew version of the PTSD Inventory (Spivak et al 1997).  227 
Cross-sectional studies measuring IL-1β in-vivo. Five of the included cross-sectional studies identified 228 
elevated IL-1β concentrations in the plasma or serum of PTSD participants, as compared to a control 229 
group (Hoge et al 2009; Oganesyan et al 2009; Spivak et al 1997; Tucker et al 2004; Zimmerman et al 230 
2012). The remaining five studies found no difference in serum or plasma concentrations of IL-1β 231 
between participants with and without PTSD (Bersani et al 2016; Jergović et al 2015; Lindqvist et al 232 
2014; von Känel et al 2007; Zhou et al 2014). Details of these studies are presented in Table II. 233 
Of note, plasma IL-1β concentration were found to positively correlate with recognised PTSD 234 
symptoms, including re-experiencing, avoidance and co-morbid anxiety and depression, although 235 
when controlling for co-variates, such as depression, the results became insignificant (von Känel et al 236 
2007). Spivak et al (1997) reported a positive correlation between serum IL-1β concentration and PTSD 237 
symptom duration. This association remained even when adjusting for subject demographics. 238 
Additionally, Oganesyan et al (2009) noted a positive correlation between IL-1β and CH50 levels, a 239 
marker measure of activation of the classic complement pathway, suggestive of an immunological 240 
component to PTSD pathophysiology. Zimmerman et al (2012) identified a significant inverse 241 
correlation between IL-1β serum levels and hippocampal volume in a subset of PTSD patients (n=5). 242 
No correlations were identified between IL-1β serum levels and other brain structures. 243 
Cross-sectional studies measuring IL-1β in-vitro. Two studies assessed IL-1β production using in-vitro 244 
methods; details regarding these are presented in Table II. Gola et al (2013) assessed spontaneous 245 
and lipopolysaccharide (LPS)-induced IL-1β production in peripheral blood mononuclear cells (PBMCs) 246 
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of refugees, with and without PTSD. Participants with PTSD were found to spontaneously produce 247 
elevated levels of IL-1β, as compared to those without PTSD. Spontaneous IL-1β production and PTSD 248 
symptom severity (in PTSD group only) were found to be correlated at trend level. However, no 249 
difference in LPS-induced IL-1β production was observed between these groups. Similarly, Gill et al 250 
(2008) found no differences between females with PTSD, females who experienced trauma but did 251 
not go on to develop PTSD, and healthy females in stimulated phytohaemagglutinin (PHA) combined 252 
with LPS production of IL-1β from whole blood samples. 253 
Longitudinal studies measuring IL-1β in-vivo. Two of the included studies employed a longitudinal 254 
design (Jergović et al 2015; Tucker et al 2004). The results of these studies are presented in Table II. 255 
In Jergović et al (2015), serum IL-1β was measured on two separate occasions, three months apart, in 256 
male Croatian combat veterans with PTSD. An increase in IL-1β concentration was found between the 257 
first and second assessment. Of note, IL-1β was not detectable in a proportion of participants at both 258 
time points. Tucker et al (2004) performed a double-blind randomised controlled trial of selective 259 
serotonin reuptake inhibitors (sertraline and citalopram) and placebo treatment in outpatients with 260 
PTSD. In contrast to Jergović et al (2015), serum IL-1β was found to significantly decrease over the trial 261 
for all treatment groups.  262 
INSERT TABLE II HERE 263 
Discussion 264 
The current review summarises and integrates the existing data on concentrations and production of 265 
IL-1β in PTSD. Data from the included animal studies demonstrated an increase in serum IL-1β 266 
concentration and a time-dependent elevation in hippocampal IL-1β levels in PTSD-modelled rats 267 
(Aga-Mizrachi et al 2014; Jones et al 2015; Lazuko et al 2017; Lee et al 2016; Peng et al 2013). In 268 
particular, this was observed in the dentate gyrus of the dorsal hippocampus, suggesting that 269 
inflammation in this neural region, with roles in memory processing and autonomic functions, may be 270 
integral to PTSD pathophysiology. Conversely, no difference in IL-1β levels between PTSD-modelled 271 
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rats and controls was observed in three studies (Deslauriers et al 2017; Liu et al 2016; Zimmerman et 272 
al 2012), highlighting the need for further research into cytokine levels in animal models of PTSD. As 273 
a centre for emotional processing, dysregulation of inflammatory processes in the amygdala may 274 
equally contribute to PTSD symptoms, particularly those effecting mood (Shin et al 2006). However, 275 
Jones et al. identified no increase in IL-1β in the basolateral amygdala. More research is needed to 276 
assess IL-1β levels in alternative neural regions that have been implicated in PTSD. 277 
Interestingly, in the animal studies a range of treatment medications were found to reduce both IL-1β 278 
levels and PTSD-like behaviours, including antidepressants (Aga-Mizrachi et al 2014), apocynin, an 279 
inhibitor of NADPH oxidase (Liu et al 2016), and gastrodin, an inhibitor of nitric oxide synthase (Peng 280 
et al 2013). This not only contributes further evidence to the role of oxidative stress and inflammatory 281 
mechanisms in PTSD pathophysiology, but also suggests that such compounds may be useful as future 282 
pharmacological therapies for PTSD. Similarly, morphine was found to decrease IL-1β in the dorsal 283 
hippocampus (Jones et al 2015), suggestive of a protective role of opioid signalling in the physiological 284 
response to trauma. In summary, the majority of animal studies suggest an associative link between 285 
elevated IL-1β and PTSD; however, the small number of animal studies identified in this review makes 286 
drawing solid conclusions difficult, particularly concerning serum IL-1β, where only three studies were 287 
available. 288 
Half of the human cross-sectional studies found that serum or plasma IL-1β concentrations were 289 
elevated in those with PTSD compared to control participants (Hoge et al 2009; Oganesyan et al 2009; 290 
Spivak et al 1997; Tucker et al 2004; Zimmerman et al 2012). Spontaneous production of IL-1β was 291 
also found to be elevated in PTSD compared to non-PTSD groups (Gola et al 2013). The remaining 292 
studies found no significant difference in serum or plasma IL-1β concentrations between PTSD 293 
patients and controls (Bersani et al 2016; Lindqvist et al 2014; von Känel et al 2007; Zhou et al 2014) 294 
(Jergović et al 2015). Stimulated production of IL-1β also did not differ between PTSD and control 295 
groups (Gill et al 2008; Gola et al 2013). One factor that may contribute to the variable outcomes 296 
Waheed, Dalton, et al.  
13 
 
observed is participant’s use of corticosteroid treatments (e.g. prednisone, prednisolone and 297 
dexamethasone). These medications have anti-inflammatory effects (Greaves 1976), however, long-298 
term steroid treatment was an exclusion criteria in only one study (Zhou et al 2014). Given the mixed 299 
findings and the lack of control for potential confounders such as glucocorticoid treatment, it would 300 
be premature to consider IL-1β as a biomarker of PTSD. Moreover, given that other pro-inflammatory 301 
cytokines (e.g. Il-6 and TNF-α) were also shown to be elevated in patients with PTSD, as compared to 302 
controls, a combined pro-inflammatory cytokine score/index may be most appropriate as a biomarker. 303 
In addition, levels of these cytokines, and others, are typically elevated in people with moderate to 304 
severe depression (Dahl et al 2014). Therefore, cytokine levels may be a general marker of 305 
psychopathology, rather than specifically for PTSD.  306 
There is much evidence from animal studies showing that both chronic and acute stress paradigms 307 
result in elevated levels of pro-inflammatory cytokines (e.g. Cosen-Binker et al 2004; Liu et al 2012). 308 
This includes elevated protein and mRNA levels of IL-1β in the brain (e.g. Minami et al 1991; Nguyen 309 
et al 1998; Pugh et al 1999). Furthermore, in humans, acute psychological stress has been shown to 310 
increase IL-1β gene expression (Brydon et al 2005). The mechanisms as to how stress leads to an 311 
increase of pro-inflammatory cytokine production is still unclear. Pro-inflammatory cytokines, 312 
including IL-1β, have an effect on the brain, and therefore, behaviour, via several mechanisms (Quan 313 
2008). For example, they have been shown to have effects on neurotransmitter synthesis, release and 314 
reuptake; neuroendocrine activity; neural plasticity; and changes in brain circuitry (Capuron and Miller 315 
2011). Therefore, stress may results in an increased production of pro-inflammatory cytokines and 316 
consequently trigger neurobiological changes, which may contribute to the development and/or 317 
maintenance of psychiatric disorders, such as PTSD and depression.  318 
As previously mentioned, the hippocampus is a key brain structure implicated in PTSD (e.g. Kitayama 319 
et al 2005; O'Doherty et al 2015). In the animal studies described above, elevated IL-1β was observed 320 
in the hippocampi of PTSD-modelled rats and in one of the included human studies, IL-1β serum levels 321 
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were found to be inversely correlated with hippocampal volume in PTSD patients (Zimmerman et al 322 
2012) which may imply that elevated IL-1β production possibly leads to a decrease in hippocampal 323 
volume. Moreover, it has been suggested that elevated IL-1β concentration in the hippocampus may 324 
impair synaptic plasticity and memory (Patterson, 2015). However, the mechanisms as to how IL-1β 325 
influences hippocampal volume and synaptic plasticity are not clear.  326 
Only two longitudinal studies of IL-1β levels in PTSD patients were identified in this review, reporting 327 
contradictory findings in terms of IL-1β, however, both finding improvements in PTSD symptoms 328 
(Jergović et al 2015; Tucker et al 2004). Specifically, in a randomised controlled trial of anti-depressant 329 
medications (placebo vs. sertraline vs. citalopram), all treatment groups showed decreases in serum 330 
IL-1β at the end of treatment, compared to baseline (Tucker et al 2004). In contrast, Jergović et al 331 
(2015) found that serum concentrations of IL-1β increased over a period of 3-months. However, in 332 
approximately half of the samples IL-1β could not be detected, and this therefore limits our ability to 333 
draw firm conclusions. As there is limited longitudinal data on IL-1β concentrations in PTSD, future 334 
research should measure IL-1β over the treatment course to better determine how IL-1β is related to 335 
changes in PTSD symptom severity and associated treatment response. Given not everyone who is 336 
exposed to a traumatic event will go on to develop PTSD, prospective studies would also be of benefit 337 
in elucidating the role of cytokines in the development and maintenance of PTSD (Keane et al. 2009). 338 
Methodological considerations of the included studies. Many of the included studies did not covary for 339 
potential confounding variables in their analyses or study design that could affect the cytokine 340 
concentration, for example, BMI, smoking, medication (e.g. corticosteroid treatments), blood sugar 341 
level and total cholesterol. High co-morbid rates of dyslipidaemia, coronary heart disease, smoking 342 
and obesity amongst PTSD sufferers have been observed. Given that factors associated with these 343 
(e.g. BMI, physical illnesses, medication, smoking; Dugué et al 1996) have been shown to impact upon 344 
cytokine concentrations, it would be important for future studies to take factors such as these into 345 
consideration. Another factor to take into consideration is that the studies included in the current 346 
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review used different PTSD assessment/diagnostic tools. The measures used to assess PTSD symptoms 347 
vary considerably on a range of factors, including number of items, response format, time frame, and 348 
degree of detailed enquiry. Therefore, studies may not be directly comparable with regards to PTSD 349 
symptom severity. 350 
There are also several limitations of the included studies based on factors related to the sample that 351 
limit the generalisability of the findings. Generally, sample sizes are small and the majority of study’s 352 
samples consisted of exclusively or predominantly males. This may be attributable to the inclination 353 
to study combat-associated PTSD, with males being more highly represented in armed services. 354 
However, considering the increased incidence of PTSD in females (Carmassi et al 2014), the presented 355 
data may not be able to account for potential sex differences in IL-1β levels and may not be 356 
generalisable to females with PTSD. Furthermore, many samples are limited to veterans with trauma 357 
exposure due to combat. We cannot be sure that individuals with different experiences of trauma 358 
exposure (e.g. with regards to time, type and extent of trauma exposure) will demonstrate similar 359 
alterations in cytokine levels (Wang and Young 2016). Future studies should consider investigating 360 
cytokine levels in non-military PTSD patients. Finally, several of the included studies used trauma 361 
controls, i.e. people that had previously been exposed to trauma (e.g. combat) but did not go on to 362 
develop PTSD, which may account for the findings observed in some of the studies. Although not 363 
meeting the clinical threshold for a formal PTSD diagnosis, the experience of trauma may cause 364 
intrinsic changes in cellular processes, which may result in a heightened pro-inflammatory status in 365 
the control group participants. For example, MRI studies have since shown cingulate isthmus and 366 
prefrontal volume reduction, not only in PTSD individuals, but also in those without diagnosed PTSD 367 
who have been previously exposed to traumatic events (Eckart et al 2011). However, it is still unclear 368 
as to what extent trauma exposure can influence inflammatory markers, even without the 369 
development of PTSD (Passos et al 2015).  370 
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Limitations of the current review. Our systematic review has a number of limitations. Firstly, PubMed 371 
was the only source of articles searched, potentially excluding some of the published literature on the 372 
subject. However, a hand-search was also conducted to identify any that may have been missed 373 
through the initial search. Secondly, given that several other pro- and anti-inflammatory cytokines 374 
have been implicated in PTSD, the exclusive focus on IL-1β may be deemed too narrow. Thirdly, as 375 
several of studies in this review, both animal and human, reported elevated IL-1β in PTSD groups, 376 
publication bias must also be taken into account.  377 
Conclusion 378 
Animal studies suggest that IL-1β expression/production, particularly in the hippocampus, may be 379 
involved in the underlying pathophysiology of PTSD. Anti-inflammatory agents were shown to reduce 380 
elevated IL-1β levels in animal studies, and therefore may be a potential basis for future therapeutic 381 
agents in PTSD treatment. The conflicting findings from human studies suggest that it is premature to 382 
consider IL-1β as a biomarker of PTSD. However, these findings need to be considered in light of a 383 
range of methodological issues, such as confounding variables and sample characteristics. Therefore, 384 
more research, taking into account these issues, is needed to determine whether IL-1β can be 385 
considered a specific biomarker of, PTSD and therefore a potential therapeutic target for PTSD. 386 
Longitudinal research is needed to better understand the role of IL-1β in the development and/or 387 
maintenance of PTSD. 388 
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